Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Association between spikes and particles
The use of a spike (large bore needles) to prepare the dose may produce stopper fragments. Lilly does NOT recommend the use of spikes with Alimta. If particulate matter is observed, do not administer.
The primary contributor of particulate matter in vial presentations originates from the rubber closure (stopper). Therefore, particles observed after reconstitution might originate from puncturing the stopper with the needle.1
Many elements can influence the production of stopper fragments during reconstitution including:1
Needle type: Blunt needle tips have a much greater tendency to produce fragments than sharp tips.
Needle gauge: Needles larger than 21-gauge tend to promote fragmentation.
Force of puncture: Lower needle insertion forces reduce the tendency to produce fragments.
Angle of puncture: Needle insertion at a 45° angle to the plane of the stopper reduces the likelihood of fragments.
Incorrect use: Using a spike on a stopper design that was not intended to receive a spike will produce fragments.
Although particles may arise during the manufacturing process Alimta is produced using the stringent manufacturing controls and undergoing inspection and sorting procedures to reduce the potential presence of any atypical vials as low as possible. Other sources of particles can also include the diluent, needle, tubing or administration sets used during the infusion.1
If particles are observed
Parenteral medicinal products must be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.2
2. Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands
Date of Last Review: 20 May 2021